Pay in 4 interest-free payments of $7.05 Learn more
Ships within 48 hours · Estimated delivery Jul 27 - Aug 1
there is not enough scientific data to prove their safety
Semaglutide has been tested in several robust clinical development programs and outcome studies in cardiometabolic diseases, including type 2 diabetes, obesity, cardiovascular disease, heart failure, chronic kidney disease, liver disease and other related cardiometabolic diseases
PMID: 83 ZingoneFBaiJCCellierCLudvigssonJF
Looking good shouldn't put your health at risk
Common Side Effects Injection site reactions Headache Flushing Mild fluid retention Metabolic and Hormonal Considerations Potential alterations in glucose metabolism Elevated IGF-1 levels Theoretical risk of promoting tumor growth in predisposed individuals Key Limitation Most safety data comes from: Pediatric GH deficiency populations Adults with endocrine disorders There is limited long-term data in healthy, high-performing athletes
In this industry, that matters a great deal
US$ 21.84
US$ 28.37
US$ 20.32
US$ 26.55